anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A non-aqueous topical composition comprising moxidectin, 1-50% of at least one C1-C6 alcohol, 1-20% of at least one thickener and a pharmaceutically acceptable oil. The composition may comprise 0.01-5% moxidectin. The alcohol may be isopropyl alcohol. The thickener may be polybutene, preferably with a molecular weight from 810 to 1800. The oil may be medium-chain triglycerides, particularly caprylic/capric triglycerides. The composition may also comprise a penetration enhancer such as PPG-2 myristyl ether propionate and at least one antioxidant such as tert-butyl hydroquinone, butylated hydroxyanisole or citric acid. The composition is for use as a medicament and/or in the treatment or prevention of endoparasites and/or ectoparasites in animals, particularly cats, dogs, sheep, cows or horses. The composition is produced by mixing the components in a nitrogen-rich oxygen-free atmosphere.
Subjects will receive nutritional intervention by a registered dietician and a flavonoid-enriched juice supplement for 8 weeks. The dietary intervention consists of healthy dietary recommendations and hypocaloric diet if necessary (overweight, obesity).
PURPOSE: An essential oil of Zanthoxyli fructus is provided to enhance ALP activity, collagen synthesis, calcium accumulation, to promote bone formation, and to be used as a pharmacological formulation for treating osteoporosis. CONSTITUTION: A pharmaceutical composition for preventing or treating osteoporosis contains essential oil of Zanthoxyli fructus as an active ingredient. The essential oil is prepared by steam distillation, hot water distillation, oil adsorption, solvent extraction, supercritical fluid extraction, or pressing. The essential oil contains one or more kinds of compounds selected from the group consisting of beta-phellandren, citronellal, geranyl acetate, beta-myrcene, citronellyl acetate, acetate, citronellol, krypton, linalool, cuminol, nonanoic acid, alpha-terpinolene, geranial, and piperitone. Health food for treating osteoporosis contains the essential oil of Zanthoxyli fructus as an active ingredient. [Reference numerals] (AA) Cell growth(%); (BB) Zanthoxyli fructus essential oil(ug/mL)
PROBLEM TO BE SOLVED: To produce colorless glucosides useful as a surfactant or a fragrance enhancing agent for plant such as cut flower in high yield and purity by reacting a glucose compound with an alcohol in the presence of an acid catalyst under reduced pressure. SOLUTION: The objective glucoside expressed by the formula (e.g. 2- phenylethyl glucoside) and useful as a surfactant or a fragrance enhancing agent for a plant such as a cut flower, etc., is produced in high yield and purity by reacting a glucose compound expressed by formula I (wavy line represents α- or β-configuration) (e.g. D-glucose anhydride) with an alcohol expressed by formula ROH (R is an aliphatic alcohol residue, an aromatic alcohol residue or an alicyclic alcohol residue) (e.g. 2-phenylethyl alcohol) under reduced pressure in the presence of an acid catalyst (e.g. acidic ion-exchange resin) at 75-85 deg.C for 24hr.
Participants receive one office-based counseling session and 4 phone-delivered counseling sessions focused on general health and nutrition strategies using a model of behavioral self regulation skills building. Participants also receive follow-up medication reminder text messages delivered by cell phone.
Tacrolimus capsules, USP are available in 0.5 mg, 1 mg, and 5 mg strengths. 

Tacrolimus capsules, USP containing white to off white powder equivalent to 0.5 mg of anhydrous tacrolimus, are hard gelatin capsules with white opaque body and ivory cap. The body is imprinted ‘643’ and cap is imprinted ‘’ in black ink.

Tacrolimus capsules, USP containing white to off white powder equivalent to 1 mg of anhydrous tacrolimus, are hard gelatin capsules with white opaque body and brown cap. The body is imprinted ‘644’ and cap is imprinted ‘’ in black ink.

Tacrolimus capsules, USP containing white to off white powder equivalent to 5 mg of anhydrous tacrolimus, are hard gelatin capsules with white opaque body and orange cap. The body is imprinted ‘645’ and cap is imprinted ‘’ in black ink.
BACKGROUND: Chromosome 16p11.2 deletions and duplications were found to be the second most common copy number variation (CNV) reported in cases with clinical presentation suggestive of chromosomal syndromes. Chromosome 16p11.2 deletion syndrome shows remarkable phenotypic heterogeneity with a wide variability of presentation extending from normal development and cognition to severe phenotypes. The clinical spectrum ranges from neurocognitive and global developmental delay (GDD), intellectual disability, and language defects (dysarthria /apraxia) to neuropsychiatric and autism spectrum disorders. Other presentations include dysmorphic features, congenital malformations, insulin resistance, and a tendency for obesity. Our study aims to narrow the gap of knowledge in Saudi Arabia and the Middle Eastern and Northern African (MENA) region about genetic disorders, particularly CNV-associated disorders. Despite their rarity, genetic studies in the MENA region revealed high potential with remarkable genetic and phenotypic novelty.
RESULTS: We identified a heterozygous de novo recurrent proximal chromosome 16p11.2 microdeletion by microarray (arr[GRCh38]16p11.2(29555974_30166595)x1) [(arr[GRCh37]16p11.2(29567295_30177916)x1)] and confirmed by whole exome sequencing (arr[GRCh37]16p11.2(29635211_30199850)x1). We report a Saudi girl with severe motor and cognitive disability, myoclonic epilepsy, deafness, and visual impairment carrying the above-described deletion. Our study broadens the known phenotypic spectrum associated with recurrent proximal 16p11.2 microdeletion syndrome to include developmental dysplasia of the hip, optic atrophy, and a flat retina. Notably, the patient exhibited a rare combination of microcephaly, features consistent with the Dandy-Walker spectrum, and a thin corpus callosum (TCC), which are extremely infrequent presentations in patients with the 16p11.2 microdeletion. Additionally, the patient displayed areas of skin and hair hypopigmentation, attributed to a homozygous hypomorphic allele in the TYR gene.
CONCLUSION: This report expands on the clinical phenotype associated with proximal 16p11.2 microdeletion syndrome, highlighting the potential of genetic research in Saudi Arabia and the MENA region. It underscores the importance of similar future studies.
FIELD: biotechnology, pharmacy. SUBSTANCE: method involves separate culturing strains of bifidobacteria and lactic acid bacteria and their mixing in the ratio 1:1 after culturing termination. Culturing is carried out on hydrolyzate- milk medium. Hydrolyzate of defatted milk is used as a base and ascorbic acid is added additionally in the amount 230-250 mg/1000 ml of hydrolyzate. Ready preparation is packaged into bottles taking into account the daily dose. Method ensures to obtain preparation ready for using that effects on bifido- and lactic acid components of human microflora. EFFECT: improved method of preparing, prolonged time of fitness. 2 cl
Loratadine 10 mg (1 mg/ml) syrup once daily for 2 weeks. Subjects who were randomized to receive loratadine syrup also received placebo syrup. Each subject was instructed to take 2 teaspoons from Bottle A and 2 teaspoons from Bottle B once daily, before 10:00 AM.
Chemokines belongs to a large group of small chemotactic proteins (8-11 kilodaltons in size). Upon engagement of chemokine, chemokine receptor can activate downstream intracellular signaling pathways and results in diverse cellular processing such as cytoskeleton reorganization and cell locomotion. Chemokines are chemoattractant factors and can stimulate directional migration of all classes of leukocytes such as T cells. Epidermal keratinocytes in the skin are able to express multiple chemokines that can attract certain leukocytes, such as T cells or dendritic cells (DCs), to migrate to the epidermis. Psoriasis is a type of skin inflammatory diseases that results in misregulated immune system including immune cell infiltration. Keratinocyte secreted chemokine and chemokine receptor on leukocytes have been known to involve in the pathogenesis of psoriasis. However, it is not very clear how chemokines are regulated in keratinocytes and the binding of chemokine to receptor on leukocytes controls the pathogenesis of psoriasis. To better understand the immune regulation of chemokine and chemokine receptor in the molecular mechanism and pathogenesis of psoriasis, the investigators plan to establish human psoriasis skin xenograft mouse model that involves graft of human skin onto immune deficient mice. The human skin, including lesional and non-lesional skins, has been proven to be acceptable to the SCID mice and the phenotype can maintain for a number of months. The advantage of the xenograft model is to that it can preserve the full complexity of human diseases and thus resembles the pathogenesis of human diseases. This model has also been shown with constant efficacy of anti-psoriasis drug in comparison with clinical practice. Thus, this mouse model has great value to help the investigators understand how chemokine and immune cells are regulated in psoriasis. Of particular note is that this model can be used to test therapeutic drug before introduce them into clinical trial.
The women were allowed to empty their urinary bladder before induction of anesthesia, but catheterization was not performed. After positioning the patient appropriately on the operating table, bimanual pelvic examination was performed under anesthesia to assess the axis and the size of the uterus. A Sim's speculum was inserted into the vagina; the cervix was visualized and grasped using the Vulsellum forceps. The cervical canal was dilated gradually with Hegar dilators up to the size corresponding to the weeks of gestation. The uterine cavity was evacuated using a plastic cannula attached to an electric suction apparatus. Negative pressure of 75 mmHg was used. The aspirate was examined to confirm the presence of products of conception. The completeness of the evacuation was checked by gentle sharp curettage and final suctioning at the end of procedure.
Posaconazole is primarily metabolized via UDP glucuronosyltransferase and is a substrate of p-glycoprotein (P-gp) efflux. Therefore, inhibitors or inducers of these clearance pathways may affect posaconazole plasma concentrations. Coadministration of drugs that can decrease the plasma concentrations of posaconazole should generally be avoided unless the benefit outweighs the risk. If such drugs are necessary, patients should be monitored closely for breakthrough fungal infections. 

Posaconazole is also a strong inhibitor of CYP3A4. Therefore, plasma concentrations of drugs predominantly metabolized by CYP3A4 may be increased by posaconazole [see Clinical Pharmacology (12.3)]. 

The following information was derived from data with Noxafil ® oral suspension or early tablet formulation unless otherwise noted. All drug interactions with Noxafil ® oral suspension, except for those that affect the absorption of posaconazole (via gastric pH and motility), are considered relevant to posaconazole delayed-release tablet, as well [see Drug Interactions (7.9) and (7.13)].
The invention is a kind of whole rhizome gastrodiae soft capsule and the manufacturing method. The rhizome gastrodiae is crushed into tiny powder of 890-100 items, and then they are put into super tiny disintegrator to be crushed into tiny powder of 400-500 items. Then, sterilizing, the edible oil and beeswax are put in and blended evenly. They are filled and compressed into capsules. Comparing with current technology, the invention produces the rhizome gastrodiae into cell grade powder, so the effective material in cell breaks out. It enhances the absorption of the medicine and the utilization ratio. The medicine has prominent effect on headache, limbs numb, falling sickness.
The investigators will enroll a total of 600 eligible consenting women patients who will be randomized to a Brief Intervention Group (BIG) n=240, an Assessed Care Group (ACG) n=240 or to a No Contact Control Group (NCCG) n=120, that is screened for eligibility and provides basic demographic information but has no further contact with researchers until they are assessed for outcomes only at 3 months. All participants will complete an initial Social Health Survey, a form distributed routinely to all patients in the ED which gives patients an opportunity to self-disclose a variety of social and behavioral risks as part of routine care. As part of the study, patients who disclose any IPV or drinking risk will be asked to complete a further screening (CTS2S and AUDIT) to confirm eligibility prior to randomization. The experimental group (BIG) will receive a 20 minute manual driven, optionally audio-recorded MET intervention by a Motivational Interview (MI)-trained therapist during their ED visit and a 10-15 minute phone booster at 7 to 10 days. The BIG and ACG will be assessed at baseline using the Women's Health Interview to identify potential moderators of the intervention and followed weekly for IPV and drinking outcomes using an Interactive Voice Response System (IVRS) for 12 weeks and phone assessments at 3, 6, and 12 months.

Primary outcomes, assessed for all groups at 3 months, will be the number of heavy drinking days and the incidents of IPV in the last month. Secondary outcomes include number of severe IPV incidents and average weekly alcohol consumption. The investigators will also assess likely mediators of the intervention. Protocol for follow-up contact will be determined by a plan developed by the participant and the MET interventionist. Should a participant decide that it is unsafe to be contacted via telephone, she will be given the option to complete any or all follow-up in the ED. Each time the patient is contacted for follow-up, the researcher will ask if the plan for contact has changed and will implement the necessary changes during the subsequent contacts. In addition, participants will be told that they can contact the PI using the contact information provided on the study's consent materials if the plan changes between contacts. Participants will also be asked at each follow-up contact if they are still interested in participating in the Women's Health Study to ensure ongoing consent. They may decide not to continue participation, and do not need to provide a reason for withdrawal from the study.
Risk Summary   
There are no data on the presence of gadopiclenol in human milk, the effects on the breastfed infant, or the effects on milk production. However, published lactation data on other GBCAs indicate that 0.01% to 0.04% of the maternal gadolinium dose is excreted in breast milk. Additionally, there is limited GBCA gastrointestinal absorption in the breast-fed infant. Gadopiclenol is present in rat milk. When a drug is present in animal milk, it is likely that the drug will be present in human milk (see Data). The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Vueway and any potential adverse effects on the breastfed infant from Vueway or from the underlying maternal condition.

Data   
In lactating rats receiving single intravenous injection of [153Gd]-gadopiclenol, 0.3% and 0.2% of the total administered radioactivity was transferred to the pups via maternal milk at 6 hours and 24 hours after administration, respectively. Furthermore, in nursing rat pups, oral absorption of gadopiclenol was 3.6%.
Practical blood flow restriction (pBFR), using non-pneumatic elastic cuffs, is a feasible and cost-effective alternative to pneumatic systems. There is evidence that cuff stiffness influences haemodynamic and perceptual responses in the upper body during rest. However, the impact of cuff stiffness during exercise is still unknown. Therefore, this study investigated the influence of cuff stiffness on physiological, perceptual, and performance changes during exercise. In a randomized and counterbalanced order, ten recreationally active males performed four sets of unilateral elbow flexions at 20% of individuals' one-repetition-maximum with two elastic cuffs of different stiffness (low stiffness cuff [LS] and high stiffness cuff [HS]) each applied with two different overlaps (10% and 20% overlap in relation to the limb circumference) as well as a control condition without pBFR. Before and after exercise, maximal voluntary isometric contraction torque was measured to assess motor performance fatigue. During exercise, muscle oxygen saturation of the biceps brachii as well as effort and exercise-induced muscle pain perception were recorded. Statistical analysis revealed that motor performance fatigue was not different between conditions (BF10 = 0.289). The decline in muscle oxygen saturation (BF10 = 8.508 and BF10 = 1039.543) as well as effort (BF10 = 2646.104 and BF10 = 2.773∙106) and exercise-induced muscle pain perception (BF10 = 14087.983 and BF10 = 7.306∙109) were higher when using the stiffer cuff at 10% and 20% overlap, respectively. Conclusively, physiological and perceptual responses but not motor performance fatigue were affected by cuff stiffness when equal relative overlaps were applied.
INTRODUCTION: Tinnitus is a common ailment that affects 10%-15% of adults worldwide. Comorbidities associated with tinnitus often include hearing loss, emotional distress and sleep disorders, with insomnia being a common issue among patients with tinnitus. Audiological and psychological approaches are typically used to treat chronic subjective tinnitus, with the combination of sound therapy and cognitive-behavioural therapy-based counselling having the strongest evidence for effectiveness. Acceptance and commitment therapy (ACT) has also shown promising effects in reducing the impact of tinnitus when delivered in groups or online. However, there is a lack of evidence on the effects of combining ACT with sound therapy for patients with tinnitus-related insomnia. Therefore, this study aims to compare the efficacy of internet-delivered ACT combined with sound therapy versus sound therapy alone for tinnitus in a superiority, two-arm randomised controlled trial.
METHODS AND ANALYSIS: A total of 164 patients with chronic subjective tinnitus and insomnia will be randomised to receive internet-delivered guided self-help tinnitus treatment based on ACT combined with tailored sound therapy or tailored sound therapy alone. The primary outcome is the variation in Tinnitus Handicap Inventory scores observed 2 months after randomisation between the two study groups. Secondary outcomes will include insomnia severity, sleep parameters, tinnitus loudness, tinnitus acceptance, depression and anxiety. The outcomes will be assessed at 2, 3 and 6 months post randomisation.
ETHICS AND DISSEMINATION: The study is approved by the review board and ethics committee of the Eye and ENT Hospital of Fudan University (approval number: 2023066-1). The findings will be disseminated through presentations at relevant conferences and peer-reviewed publications.
TRIAL REGISTRATION NUMBER: NCT05963542.
Schizophrenia is a chronic condition characterized by positive symptoms (auditory hallucinations, delusion), negative symptoms (avolition, social withdrawal), and disorganized thoughts/behaviors. Although the pathophysiology is incompletely understood, several neurobiological mechanisms have been proposed. Treatment usually involves antipsychotic medication as well as psychotherapy and supportive services. When evaluating patients in the emergency department, acute safety considerations are paramount. Patients should be assessed for suicide risk, violence risk, inability to care for self, and the risk of being the victim of a crime. Persons with schizophrenia are at an increased risk of substance use and a variety of medical problems.
The purpose of this study is to determine whether SF2a-TT15 (a monovalent synthetic carbohydrate-based conjugate Shigella vaccine) is safe and effective in the prevention of Shigella infection. This will be a phase 2b, double-blind, placebo-controlled, single-center study, involving a vaccination phase and a challenge phase. The vaccination phase will consist of study participants that will be 1:1 randomized to receive either the vaccine or placebo. Two doses of blinded study product will be given by intramuscular route of administration, separated by approximately 4 weeks. The challenge phase will consist of an inpatient stay of approximately 12 days during which eligible study participants will ingest an oral inoculum of wild-type S flexneri 2a strain 2457T and then be monitored for illness and treated with antibiotics when the primary endpoint is reached or upon 5 days post-challenge, whichever comes first, or when deemed necessary. Upon satisfying discharge criteria, study participants will complete outpatient clinic follow-up visits through \~7 months after last dose of blinded study product (Day 237). The efficacy study will be enrolled through three cohorts of participants, each cohort consisting of approximately 30 subjects that will be involved in the vaccination phase and 22 subjects that will proceed with the challenge phase. There will be a fourth cohort of participants, consisting of 12 subjects, that will receive the vaccine in an open-label design-this cohort will provide serum samples which are intended to be used for generating serum standards for laboratory assays, as a part of ongoing and future clinical development of Shigella vaccines.
This randomized controlled trial was conducted to assess the effectiveness of a family-based and mobile-assisted lifestyle intervention in reducing weight gain among school-age children with overweight and obesity. A total of 164 school-age children with overweight or obesity and their parents were randomized to the treatment intervention (n = 82) or an attention-control group (n = 82). The treatment intervention included three face-to-face education sessions, augmented by monthly text messages sent to parents on their mobile devices. The primary outcome was child BMI-for-age z-score. Secondary outcomes included child BMI, percent body fat, and actigraphy-assessed sleep as well as parental sleep quality. Outcomes were assessed at baseline, 3, 6, and 12 months after the intervention, with treatment effects analyzed using general linear models for repeated measures. Our results showed that children in the treatment intervention group had significantly lower BMI-for-age z score, BMI, and percent body fat than did those in the control group, with an adjusted mean difference of 0.31 units (95% CI: -0.59 to -0.03; p = 0.03), 1.34 kg/m² (95% CI, -2.42 to -0.26; p = 0.01), and 3.12% (95% CI, -5.93 to -0.30; p = 0.03), respectively. No treatment effects were observed for child and parental sleep. Our findings suggest that family-based and mobile-assisted lifestyle intervention results in significant and sustained benefits to enhanced weight management for school-age children with overweight and obesity. Nurses planning and delivering childhood overweight and obesity treatment interventions should consider a family-based approach with the assistance of mobile devices.
To provide a contrast medium that allows contrast imaging of a lumenal organ with high resolution.SOLUTION: A contrast medium is provided. When an X-ray image or an ultrasonic image of a lumenal organ of an animal is taken, the contrast medium is injected into the animal organ, the contrast medium containing titanium oxide (IV) particles. The contrast medium is a dispersion of the titanium oxide (IV) particles. The titanium oxide (IV) particles have a primary particle size of 1 nm to 500 nm. When the total of components contained in the contrast medium is 100% (weight), the content of the titanium oxide (IV) particles is 3%(weight/weight) to 55%(weight/weight). The contrast medium is not one used for living humans.SELECTED DRAWING: None